Recommended Initial Treatment for Polyarteritis Nodosa (PAN)
For severe PAN, initiate cyclophosphamide combined with high-dose glucocorticoids; for non-severe PAN, use a non-glucocorticoid immunosuppressive agent (methotrexate or azathioprine) with glucocorticoids. 1
Treatment Algorithm Based on Disease Severity
Severe PAN (Life-threatening or major organ involvement)
Remission Induction:
- Cyclophosphamide PLUS high-dose glucocorticoids is the recommended combination over glucocorticoids alone 1
- Consider IV pulse glucocorticoids (methylprednisolone 500-1,000 mg/day for 3-5 days) over high-dose oral glucocorticoids for initial treatment 1
- High-dose oral glucocorticoids: Prednisone 1 mg/kg/day (adults, up to 80 mg/day) or 1-2 mg/kg/day (children, up to 60 mg/day) 1
- Cyclophosphamide is preferred over rituximab when combined with glucocorticoids 1
Important caveat: If cyclophosphamide cannot be tolerated, use other non-glucocorticoid immunosuppressive agents (methotrexate, azathioprine, or mycophenolate mofetil) with glucocorticoids rather than glucocorticoids alone 1
Do NOT add plasmapheresis to cyclophosphamide and glucocorticoids—this combination is conditionally recommended against 1
Non-Severe PAN (No life-threatening manifestations)
Remission Induction:
- Non-glucocorticoid immunosuppressive agent (methotrexate or azathioprine) PLUS glucocorticoids over glucocorticoids alone 1
- This approach reduces glucocorticoid toxicity while maintaining disease control
Critical Distinctions in Treatment Approach
Idiopathic PAN vs. Special Variants
The above recommendations apply to idiopathic systemic PAN. Two important exceptions require different management:
1. DADA2 (Deficiency of Adenosine Deaminase 2):
- Strongly recommend TNF inhibitors over glucocorticoids alone 1
- This monogenic form presents with early-onset (often childhood) PAN-like vasculitis with recurrent strokes
- TNF inhibitors prevent devastating stroke complications 1
- Consider DADA2 testing in children and young adults with PAN-like syndrome, especially with stroke history 2
2. Hepatitis B-Associated PAN:
- Requires antiviral therapy, plasma exchange, and short-term glucocorticoids 3, 4, 5
- This is a fundamentally different treatment paradigm from idiopathic PAN
Maintenance and Duration Considerations
After achieving remission with cyclophosphamide:
- Transition to another non-glucocorticoid immunosuppressive agent (methotrexate or azathioprine) rather than continuing cyclophosphamide 1
- Limit cyclophosphamide to 3-6 months per course to minimize toxicity 1
Duration of immunosuppression:
- Consider discontinuing non-glucocorticoid immunosuppressive therapy after 18 months of remission 1
- Most PAN cases are monophasic; indefinite treatment is typically unnecessary 1
Glucocorticoid tapering:
- Duration should be guided by clinical condition and patient preferences—no established optimal duration 1
- Faster tapers may lead to more flares, but these are often not organ-threatening 1
Common Pitfalls to Avoid
- Don't use rituximab as first-line therapy for idiopathic PAN—cyclophosphamide is preferred for severe disease 1
- Don't continue cyclophosphamide indefinitely—switch to maintenance agents after remission 1
- Don't forget to screen for DADA2 in young patients or those with stroke presentations, as treatment differs fundamentally 1, 2
- Don't add plasmapheresis to standard cyclophosphamide/glucocorticoid therapy in idiopathic PAN 1
Adjunctive Therapy
For patients with nerve and/or muscle involvement, add physical therapy to the treatment regimen 1
Evidence Quality Note
These recommendations are based on the 2021 ACR/Vasculitis Foundation guidelines 1, which represent the most authoritative and recent guidance. Most recommendations are conditional with very low to low evidence quality due to the rarity of PAN and lack of randomized controlled trials 1. Treatment decisions should incorporate disease severity assessment, patient values, and close monitoring for response.